MDMA-Assisted Psychotherapy

MDMA is not a classic psychedelic. It is an entactogen or empathogen: a substituted amphetamine producing large releases of serotonin, noradrenaline and dopamine, along with oxytocin and prolactin. The phenomenology is different — increased warmth, trust, emotional openness and reduced defensiveness, generally without the perceptual and self-dissolving effects of psilocybin or LSD.

The proposed mechanism, which maps onto existing trauma theory

1. 1Reduced amygdala reactivity to threatening stimuli, allowing traumatic material to be approached without the usual fear response.
2. 2Increased oxytocin, associated with trust and social bonding, supporting the therapeutic relationship at exactly the point where trauma has damaged trust.
3. 3Reduced fear-driven avoidance, permitting sustained contact with the memory — which is the active ingredient in every effective PTSD treatment.
4. 4A possible reopening of a critical period for social reward learning, proposed on the basis of animal work.
5. 5Enhanced fear extinction learning, demonstrated in animal models.

The account is standard PTSD theory. Avoidance prevents processing; the memory remains fragmented and stored with its original affective charge; and the fear response prevents the corrective learning that exposure would otherwise supply. Shame and self-blame add a second layer that exposure protocols address less well. MDMA is proposed as reducing the fear that makes both layers inaccessible.

The MAPS protocol structure, which is the reference standard.

The dosing session is deliberately inner-directed and non-directive. Therapists do not conduct imaginal exposure or lead the patient to the trauma; the instruction is to trust the process and to turn toward what arises. Whether that non-directiveness is optimal, or whether a more structured exposure protocol under MDMA would work better, has not been tested.